Reflow Medical reports zero major cardiac events at one year in nine-patient Spur Elute study
Reflow Medical has reported no major adverse cardiac events or deaths during 12 months of follow-up among nine patients treated with its investigational coronary Spur Elute system. The findings support continued development of the temporary sirolimus-delivering scaffold, but the uncontrolled pilot is too small to establish comparative effectiveness.